Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Refractory Solid Tumors

In brief

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Key facts

Study ID

NCT00394446

Run by

Myrexis Inc.

People needed

48

Starts

2005-03-01

Expected to finish

2008-02-01

Last updated by the study team

2008-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced or Metastatic Cancer
• Measurable / Evaluable Disease
• Karnofsky score greater than or equal to 70%
• Adequate Hematology / Organ function
• No Baseline peripheral or central neuropathy above grade 1

You may not qualify if…

• Hypersensitivity to Cremophor EL
• Pregnant or Lactating
• Spinal Cord Compression
• Pre-existing Dementia / Cognitive Disfunction
• Require Neupogen or Neulasta to Maintain Neutrophil Count
• Have Primary Brain Cancer
• Have history of Ischemic Heart Disease
• Have Diabetes

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.